Literature DB >> 2057656

Channeling bias in the interpretation of drug effects.

H Petri1, J Urquhart.   

Abstract

Channeling is a form of allocation bias, where drugs with similar therapeutic indications are prescribed to groups of patients with prognostic differences. Claimed advantages of a new drug may channel it to patients with special pre-existing morbidity, with the consequence that disease states can be incorrectly attributed to use of the drug. For the study of adverse drug reactions, large databases supply information on co-medication and morbidity of patients. For diseases with a stepped-care approach, the drug history of patients, as available from some databases, can show channeling of drugs to patients with markers of relatively severe disease.

Entities:  

Mesh:

Year:  1991        PMID: 2057656     DOI: 10.1002/sim.4780100409

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  70 in total

1.  Antidepressants and upper gastrointestinal bleeding.

Authors:  A L Po
Journal:  BMJ       Date:  1999-10-23

2.  Volume and market share of anti-epileptic drugs in The Netherlands: impact of new drugs.

Authors:  Pieter Knoester; Charles Deckers; Ronald van der Vaart; Bert Leufkens; Yechiel Hekster
Journal:  Pharm World Sci       Date:  2005-04

3.  Can current electronic systems meet drug safety and effectiveness requirements?

Authors:  Anne Holbrook; Paul Grootendorst; Don Willison; Charles Goldsmith; Rolf Sebaldt; Karim Keshavjee
Journal:  AMIA Annu Symp Proc       Date:  2005

4.  Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable.

Authors:  M Alan Brookhart; Philip S Wang; Daniel H Solomon; Sebastian Schneeweiss
Journal:  Epidemiology       Date:  2006-05       Impact factor: 4.822

Review 5.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

6.  Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn
Journal:  Med Care       Date:  2007-10       Impact factor: 2.983

7.  Post-approval safety issues with innovative drugs: a European cohort study.

Authors:  Peter G M Mol; Arna H Arnardottir; Domenico Motola; Patrick J Vrijlandt; Ruben G Duijnhoven; Flora M Haaijer-Ruskamp; Pieter A de Graeff; Petra Denig; Sabine M J M Straus
Journal:  Drug Saf       Date:  2013-11       Impact factor: 5.606

8.  Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Authors:  Vincent Lo Re; Bret Zeldow; Michael J Kallan; Janet P Tate; Dena M Carbonari; Sean Hennessy; Jay R Kostman; Joseph K Lim; Matthew Bidwell Goetz; Robert Gross; Amy C Justice; Jason A Roy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-19       Impact factor: 2.890

9.  Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents.

Authors:  Matthew Alcusky; Jennifer Tjia; David D McManus; Anne L Hume; Marc Fisher; Kate L Lapane
Journal:  J Gen Intern Med       Date:  2020-04-06       Impact factor: 5.128

Review 10.  Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United States.

Authors:  Ashley L Cole; Anna E Austin; Ryan P Hickson; Matthew S Dixon; Emma L Barber
Journal:  Cancer Epidemiol       Date:  2018-05-25       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.